AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02837692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 60 or 80 mg
Description: JNJ-42847922 will be administered as 3 or 4 tablets of 20 mg, orally, once on Day 1. Dose to be determined from Cohort 3, Period 1.
Study NCT02164513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate (FF)
Description: FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg
Study NCT02164513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilanterol (VI)
Description: VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
Study NCT02164513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: umeclidinium bromide (UMEC)
Description: UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg
Study NCT00798694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Xalatan
Description: one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
Study NCT00798694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Travatan Z
Description: one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime
Study NCT02027116 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-6150
Description: Plasmid DNA delivered via IM injection with electroporation
Study NCT02558153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEB, drug eluting balloon
Description: Percutaneous angioplasty performed with a DEB - drug eluting balloon
Study NCT02558153 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard PTA
Description: Percutaneous angioplasty performed with a standard balloon
Study NCT04178681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% vegetable blend
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of vegetable fat blend.
Study NCT04178681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% AMF
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat.
Study NCT00668707 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: 20 mgs ingested nightly
Study NCT00668707 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: similar to experimental in all ways except for lack of active ingredient
Study NCT04178681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% cream
Description: Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat plus milk fat globular membranes.
Study NCT04575714 — intervention group
Intervention type: OTHER
Intervention: Data record
Description: Data record
Study NCT00493454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin
Description: .3 mCi IV Over 10 Minutes x 1 Day
Study NCT03596359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education with Teach-Back method
Study NCT03596359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Received routine treatment
Study NCT03517683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low speed
Description: Speed of intrathecal injection will be 1ml in 15 seconds
Study NCT03517683 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High speed
Description: speed of intrathecal injection will be 1ml in 5 seconds
Study NCT03615469 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous electrical stimulation
Description: For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
Study NCT03615469 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrical stimulation
Description: When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt and muscle contraction is seen. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality.10,24,29-31 To assist better tolerance large electrodes (2x4) will be used and participants will also be instructed to be in a seated position with chair close to the wall so that their leg is 90-degree angle and then push against the wall to decrease any uncomfortable feeling during the contraction. 5 sessions per week for 6 weeks done independently at home, with 15 minutes per session (15 minutes per day/session, 15 seconds stimulation on, 15 seconds recovery time) to both legs. We expect the participant to develop tolerance to the treatment and thus increase the intensity of the NMES over time.
Study NCT01514188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INNO-206
Description: INNO-206 administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously (IV) on Day 1 every 21 days for up to 6 consecutive cycles
Study NCT01514188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin administered at 75 mg/m2 for up to 6 consecutive cycles.
Study NCT03452553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin
Description: Drug Eluting Beads loaded with chemotherapy
Study NCT04536740 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PDT treatment device
Description: All patients will be treated under general anesthesia. After carefully covering the normal skin, hematoporphyrin monomethyl ether (HMME; Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Shanghai, China) was i.v. transfused at a dose of 5 mg/kg for 20 min at a constant rate. Five to 10 min after the onset of HMME transfusion, continuous irradiation at 532 nm (532-nm light-emitting diode green-light therapeutic apparatus; Wuhan Yage Optic and Electronic Technique, Wuhan, China) was applied with a power density of 80- 95 mW/cm2 for 20-30 min. Concomitant forced air cooling was applied during irradiation for epidermal protection. Post-treatment skin cooling was performed by intermittent application of ice packs over a 3-day period, to minimize pain and potential thermal damage. To prevent the effects of photosensitivity, patients were instructed to avoid exposure to strong light for at least 14 days after treatment.
Study NCT04536740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDT treatment device
Description: All patients will be treated under general anesthesia. After carefully covering the normal skin, hematoporphyrin monomethyl ether (HMME; Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Shanghai, China) was i.v. transfused at a dose of 5 mg/kg for 20 min at a constant rate. Five to 10 min after the onset of HMME transfusion, continuous irradiation at 532 nm (532-nm light-emitting diode green-light therapeutic apparatus; Wuhan Yage Optic and Electronic Technique, Wuhan, China) was applied with a power density of 80- 95 mW/cm2 for 20-30 min. Concomitant forced air cooling was applied during irradiation for epidermal protection. Post-treatment skin cooling was performed by intermittent application of ice packs over a 3-day period, to minimize pain and potential thermal damage. To prevent the effects of photosensitivity, patients were instructed to avoid exposure to strong light for at least 14 days after treatment.
Study NCT04169724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm Meditation
Description: 10 minutes per day of meditation via the Calm app.
Study NCT04664595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Fresenius
Description: final dose of Propofol (mcg/kg) to reach the target effect-site concentration
Study NCT04664595 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Propofol Fresenius
Description: final dose of Propofol (mcg/kg) to reach the target effect-site concentration
Study NCT00028002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgical resection
Study NCT00028002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given orally
Study NCT00312884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HomMed Telemonitoring System
Description: The HomMed telemonitoring system allows for patients to monitor their weight, blood pressure, oxygen saturation and symptoms of dyspnoea on a daily basis from their home
Study NCT00312884 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HomMed Telemonitoring System
Description: The HomMed telemonitoring system allows for patients to monitor their weight, blood pressure, oxygen saturation and symptoms of dyspnoea on a daily basis from their home
Study NCT04393584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: d1 Irinotecan 180mg/m² every two weeks
Study NCT04393584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: d1-2 5-FU 2450 mg/m² every two weeks
Study NCT04393584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: d1-2 5-FU 2450 mg/m² every two weeks
Study NCT04393584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: d1 Leucovorin 200 mg/m² every two weeks
Study NCT04393584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: d1 Leucovorin 200 mg/m² every two weeks
Study NCT04393584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: d1 Oxaliplatin 85 mg/m² every two weeks
Study NCT04393584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: d1 Oxaliplatin 85 mg/m² every two weeks
Study NCT04393584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: d1 Docetaxel 50mg/m2 every two weeks
Study NCT01849835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans-rectal to perform the prostate biopsy
Description: the puncture points are at the rectal
Study NCT01849835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans-perineal to perform the prostate biopsy
Description: the puncture points are at the perineal
Study NCT05405465 — intervention group
Intervention type: DRUG
Intervention: Exposure to golimumab
Description: Retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
Study NCT01014000 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Empirical group
Description: Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
Study NCT01014000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiography-guided approach
Description: Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
Study NCT05112016 — intervention group
Intervention type: PROCEDURE
Intervention: Total mesorectal excision for rectal cancer
Study NCT03857763 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Apatinib,Paclitaxel,Cisplatin,RT
Description: Apatinib Mesylate Tablets 250mg qd p.o. d1-35; Paclitaxel：50mg/m2 iv d1，8，15，22，29; Cisplatin: 30mg/m2 iv d1，8，15，22，29; RT：41.4Gy/23f , 1.8Gy/f，5 f/w
Study NCT01871896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Suturing to Create Early Satiety
Description: Evaluating the efficacy of endoscopic suturing for weight loss.
Study NCT00825955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
Study NCT00825955 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
Study NCT00825955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Trans-Arterial Chemo-Embolization (TACE) Therapy
Study NCT00825955 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Trans-Arterial Chemo-Embolization (TACE) Therapy
Study NCT04652336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sleeve gastrectomy
Description: Comparator arm - will receive standard laparoscopic sleeve gastrectomy
Study NCT04652336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ligamentum teres cardiopexy with sleeve gastrectomy
Description: experimental arm - Ligamentum teres will be divided from umbilicus to up to umbilical fissure. The ligament will then be wrapped around lower esophagus and sutured.
Study NCT03677687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness for Physical Activity
Description: The Mindfulness for Physical Activity (MfPA) programme aims to change participants' relationship with physical activity by targeting psychological factors related to physical activity uptake and maintenance.
Study NCT04649203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)
Description: The study drug will be administered in two phases: intravenous infusion of study drug for 10 days followed by oral administration of study drug for 75 days. Thus, the total duration of the study therapy is 12 weeks.
Study NCT04649203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo comparator will be administered in two phases: intravenous infusion of placebo solution for 10 days followed by oral administration of placebo pills for 75 days. Thus, the total duration of the study therapy is 12 weeks.
Study NCT03699787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graphomotor intervention program
Description: The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
Study NCT03615755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy (HBOT)
Description: The investigators used 10 sessions of HBOT. One session of HBOT uses oxygen at 2.4 ATA for 90 minutes per day at multiplace hyperbaric chamber. This therapy is given five sessions in a week, so it takes two weeks.
Study NCT03047148 — intervention group
Intervention type: OTHER
Intervention: Data mining from records
Description: The relevant data for this investigation is extracted from the patient records database as well as from the assessment results of the ongoing quality control process that were collected by the nursing staff of the postoperative recovery units.
Study NCT04387058 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TIPS
Description: TIPS (Transjugular Intrahepatic Portosystemic Shunt) is an interventional radiology method that creates an anastomosis between the portal venous network and the hepatic venous network.
Study NCT01152164 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Quality of life assessment using questionnaires EORTC QLQ C30 and 38 at baseline, one year and two years after the surgery of rectal cancer, treated with preoperative capecitabine based radiochemotherapy
Study NCT03165721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110 (guadecitabine)
Description: SGI-110 will be administered subcutaneously at 45mg/m\^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.
Study NCT01126970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velneperit 400 mg
Description: Velneperit 400 mg q.d.
Study NCT01126970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat 120 mg
Description: Orlistat 120 mg t.i.d
Study NCT01241851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Study NCT01241851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise
Study NCT03696264 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acid intake
Description: Amino acid intake will range between 0.2-3.0g/kg/d
Study NCT00385268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acamprosate
Description: 1998 mg/dau fpr 8 weeks
Study NCT00385268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pills
Study NCT04087421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Qufora Irrisedo Cone System
Description: The system works by connecting a tube from a water bag to a cone. The cone is placed into the rectum and the prescribed water volume is pumped into the rectum. When the water has been installed the valve is closed and the cone removed. Residual water and stool will then flow into the toilet.
Study NCT04087421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerol OBA
Description: Rectal suppository. Stimulates the rectum and softens and loosens stool.
Study NCT04358094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conversational hypnosis script
Description: Conversational hypnosis during peripherical veinous catheter set up
Study NCT04358094 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard script
Description: Standard script during peripherical veinous catheter set up
Study NCT02131948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Description: Intranasal spray
Study NCT02131948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Intranasal spray
Study NCT03480282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prognosis information and Provider Scripts
Description: An individualized report including each patient's prognosis will be calculated by the Lee-Schonberg and will include information on patient life expectancy from Cho et al.'s US life tables. This report will be sent to the PCP three days before the patient visit. Example scripts for PCPs to use with patients when discussing life expectancy and stopping cancer screening will be sent with the patient prognostic information.
Study NCT01914419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT01943734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information passed on anthropometric assessment
Description: Information passed on worker's anthropometric assessment.
Study NCT03649321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib
Description: 200mg orally starting Cycle 1 day 2 every 21 days or 28 days.
Study NCT01126970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg
Description: Orlistat 120 mg t.i.d
Study NCT01126970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Orlistat Placebo
Description: Orlistat Placebo t.i.d.
Study NCT03649321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 25 mg/m\^2 Day 1 /8 every 21 days or 28 days.
Study NCT03649321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 Day 1 /8 every 21 days or 28 days
Study NCT03649321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/m\^2 Day 1 /8 every 21 days
Study NCT03972644 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic valve replacement
Description: Open heart surgery or transcatheter surgery
Study NCT01515995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulfate
Description: 15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour~Versus~15 mg albuterol in 22 ml of normal saline via nebulizer over one hour
Study NCT01515995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized magnesium sulfate
Description: 15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour~Versus~15 mg albuterol in 22 ml of normal saline via nebulizer over one hour
Study NCT01026701 — intervention group
Intervention type: DRUG
Intervention: bortezomib
Description: injection into a vein 1.3 mg/m2 twice a week for 21 days
Study NCT01163253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 5 mg oral BID
Study NCT01163253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg oral BID
Study NCT01672996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioforminol 160 mgI/mL
Description: Given as s single administration to the subject
Study NCT01672996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioforminol 200 mgI/mL
Description: Given as a single administration to the subject
Study NCT01672996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol 300 mgI/mL
Description: Given as a single administration to the subject
Study NCT02819310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI400 Laxative
Description: oral laxative